
This retrospective study aimed to investigate long-term outcome in patients with zzso zzso zzso treated with zzso zzso zzso Between 1998 and 2008, zzso patients with zzso received zzso Median age was 36 years zzso zzso zzso Before zzso 39 % of the patients experienced zzso and 27 % suffered from zzso seizures, whereas 43 % received previously zzso zzso % neurosurgery and zzso % zzso zzso zzso zzso was applied in zzso % of the zzso Median single dose was 19 zzso zzso % zzso range zzso zzso and median target volume was 4 zzso zzso zzso Median follow-up was 93 months zzso zzso Complete obliteration zzso was observed in 100 zzso zzso patients at a median time of 29 months zzso zzso The 3 and zzso CO rates were 61 and 88 zzso zzso In zzso analysis, radiation dose zzso 19 zzso zzso zzso zzso and target volume zzso zzso zzso zzso zzso were associated with significantly higher rates of zzso zzso zzso was seen in nine patients zzso zzso after zzso whereas three patients zzso zzso died as a consequence of zzso The annual bleeding risk was zzso % after 1 year and zzso % after 2 years, zzso In zzso analysis, only target volume zzso zzso zzso zzso zzso and zzso grade zzso zzso zzso zzso retained significance for increased risk of zzso zzso After zzso an improvement in zzso episodes, headaches and zzso deficits was found in zzso 14 and 15 % of patients, zzso Our long-term follow-up data show that zzso is an effective treatment option in zzso with low toxicity and bleeding risk, depending on zzso size and zzso zzso An improvement of zzso symptoms is zzso 

